Trial Profile
A Two-part, Phase I Open Label, Dose Escalation and Expansion Study to Assess Safety, Pharmacokinetics and Clinical Activity of NUC-3373, a Nucleotide Analogue, in Participants With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Fosifloxuridine nafalbenamide (Primary)
- Indications Basal cell cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms NuTide:301
- 13 Oct 2023 Results presented in a NuCana media release.
- 15 Apr 2021 Status changed from recruiting to completed.
- 13 Nov 2019 According to a NuCana media release, data from this study is expected in 2020.